The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors
Open accessAbstract
This study shows that induction of tumor-specific CD4+ T cells by vaccination with a specific viral T helper epitope, contained within a synthetic peptide, results in protective immunity against major histocompatibility complex (MHC) class II negative, virus-induced tumor cells. Protection was also induced against sarcoma induction by acutely transforming retrovirus. In contrast, no protective immunity was induced by vaccination with an unrelated T helper epitope. By cytokine pattern analysis, the induced CD4+ T cells were of the T helper cell 1 type. The peptide-specific CD4+ T cells did not directly recognize the tumor cells, indicating involvement of cross-priming by tumor-associated antigen-presenting cells. The main effector cells responsible for tumor eradication were identified as CD8+ cytotoxic T cells that were found to recognize a recently described immunodominant viral gag-encoded cytotoxic T lymphocyte (CTL) epitope, which is unrelated to the viral env-encoded T helper peptide sequence. Simultaneous vaccination with the tumor-specific T helper and CTL epitopes resulted in strong synergistic protection. These results indicate the crucial role of T helper cells for optimal induction of protective immunity against MHC class II negative tumor cells. Protection is dependent on tumor-specific CTLs in this model system and requires cross-priming of tumor antigens by specialized antigen-presenting cells. Thus, tumor-specific T helper epitopes have to be included in the design of epitope-based vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
Matloubian, M., Concepcion, R. J., & Ahmed, R. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8056-8063.1994 · Cited by 1,157
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Self-citationVisualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo
Kearney, E. R., Pape, K. A., Loh, D. Y., & Jenkins, M. K. (1994) · Immunity · doi:10.1016/1074-7613(94)90084-1 · Cited by 946
Feltkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minnaar, R. P., De Jongh, B. M., Drijfhout, J. W., Schegget, J. T., Melief, C. J. M., & Kast, W. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230929 · Cited by 825
Self-citationLjunggren, H. G., & Kärre, K. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.6.1745 · Cited by 736
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Miller, J. F. A. P., & Heath, W. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.65 · Cited by 725
Greenberg, P. D. (1991) · Advances in Immunology · doi:10.1016/s0065-2776(08)60778-6 · Cited by 603
Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., Sette, A., et al. (1994) · Immunity · doi:10.1016/s1074-7613(94)80017-0 · Cited by 523
Cardin, R. D., Brooks, J. W., Sarawar, S. R., & Doherty, P. C. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.863 · Cited by 501
Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
Keene, J.-A., & Forman, J. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.3.768 · Cited by 500
Cited by
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Self-citationSaxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Self-citationMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationAdvances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Sturniolo, T., Bono, E., Ding, J., Raddrizzani, L., Tuereci, O., Sahin, U., Braxenthaler, M., Gallazzi, F., Protti, M. P., Sinigaglia, F., et al. (1999) · Nature Biotechnology · doi:10.1038/9858 · Cited by 743
Gerlach, J. T., Diepolder, H. M., Jung, M., Gruener, N. H., Schraut, W. W., Zachoval, R., Hoffmann, R., Schirren, C. A., Santantonio, T., & Pape, G. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70353-7 · Cited by 714
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
“and was able to confer protection of mice against an otherwise lethal tumour challeng”
BackgroundSelf-citationSchumacher, T. N., Scheper, W., & Kvistborg, P. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 574
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Qin, Z., & Blankenstein, T. (2000) · Immunity · doi:10.1016/s1074-7613(00)80218-6 · Cited by 511
CD4 T Cells and Their Role in Antitumor Immune Responses
Toes, R. E. M., Ossendorp, F., Offringa, R., & Melief, C. J. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.753 · Cited by 508
Self-citationRoles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H., & Zinkernagel, R. M. (2001) · Nature · doi:10.1038/35082583 · Cited by 493
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3200 · Cited by 490
Primary Antitumor Immune Response Mediated by CD4+ T Cells
Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 417
Self-citationWu, K., Kryczek, I., Chen, L., Zou, W., & Welling, T. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0901 · Cited by 380
Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C.-C., Carroll, M. W., Moss, B., Rosenberg, S. A., & Restifo, N. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2982 · Cited by 381
Tumor‐specific shared antigenic peptides recognized by human T cells
Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E. S., Chapiro, J., Van den Eynde, B. J., Brasseur, F., & Boon, T. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18806.x · Cited by 378
COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and How
Castellino, F., & Germain, R. N. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115825 · Cited by 376
Combining radiotherapy and immunotherapy: A revived partnership
Demaria, S., Bhardwaj, N., McBride, W. H., & Formenti, S. C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.032 · Cited by 375
Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection
Kelly, J. M., Darcy, P. K., Markby, J. L., Godfrey, D. I., Takeda, K., Yagita, H., & Smyth, M. J. (2002) · Nature Immunology · doi:10.1038/ni746 · Cited by 356
Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity
Marzo, A. L., Kinnear, B. F., Lake, R. A., Frelinger, J. J., Collins, E. J., Robinson, B. W. S., & Scott, B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6047 · Cited by 334
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
van Montfoort, N., Borst, L., Korrer, M. J., Sluijter, M., Marijt, K. A., Santegoets, S. J., van Ham, V. J., Ehsan, I., Charoentong, P., André, P., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.028 · Cited by 333
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Tsukamoto, H., Fujieda, K., Miyashita, A., Fukushima, S., Ikeda, T., Kubo, Y., Senju, S., Ihn, H., Nishimura, Y., & Oshiumi, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0118 · Cited by 305
Active immunization against cancer with dendritic cells: The near future
Steinman, R. M., & Dhodapkar, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1503 · Cited by 299
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
Ronchetti, A., Rovere, P., Iezzi, G., Galati, G., Heltai, S., Protti, M. P., Garancini, M. P., Manfredi, A. A., Rugarli, C., & Bellone, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.130 · Cited by 293
Shrikant, P., Khoruts, A., & Mescher, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80123-5 · Cited by 283
Bijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., Offringa, R., & van der Burg, S. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5033 · Cited by 279
Self-citationSchumacher, T. N. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri841 · Cited by 274
Rosalia, R. A., Cruz, L. J., van Duikeren, S., Tromp, A. T., Silva, A. L., Jiskoot, W., de Gruijl, T., Löwik, C., Oostendorp, J., van der Burg, S. H., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.053 · Cited by 269
Self-citationThe role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity
Wang, R.-F. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01896-8 · Cited by 266
Principles of adoptive T cell cancer therapy
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31446 · Cited by 261
Second- and third-generation drugs for immuno-oncology treatment—The more the better?
Dempke, W. C. M., Fenchel, K., Uciechowski, P., & Dale, S. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.001 · Cited by 257
Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells
Mattes, J., Hulett, M., Xie, W., Hogan, S., Rothenberg, M. E., Foster, P., & Parish, C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021683 · Cited by 256
Oja, A. E., Piet, B., van der Zwan, D., Blaauwgeers, H., Mensink, M., de Kivit, S., Borst, J., Nolte, M. A., van Lier, R. A. W., Stark, R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02654 · Cited by 130
“many cancers (42), CD4 T helper cells are required to optimize cytotoxic CD8 T cell responses against tumor cells (43).”
BackgroundTsukamoto, H., Senju, S., Matsumura, K., Swain, S. L., & Nishimura, Y. (2015) · Nature Communications · doi:10.1038/ncomms7702 · Cited by 104
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Brentville, V. A., Metheringham, R. L., Gunn, B., Symonds, P., Daniels, I., Gijon, M., Cook, K., Xue, W., & Durrant, L. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1085 · Cited by 98
Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26365 · Cited by 70
Qi, L., Rojas, J.-M., & Ostrand-Rosenberg, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5451 · Cited by 60
Effector and memory CD8+ T cells as seen in immunity to malaria
Morrot, A., & Zavala, F. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00175.x · Cited by 55
Tsukamoto, H., Fujieda, K., Hirayama, M., Ikeda, T., Yuno, A., Matsumura, K., Fukuma, D., Araki, K., Mizuta, H., Nakayama, H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2446 · Cited by 53
XU, G., GUO, Y., SENG, Z., CUI, G., & QU, J. (2015) · Oncology Reports · doi:10.3892/or.2015.4174 · Cited by 35
“IL-18 activates cytotoxic T activity, augment T cell proliferation, enhance natural killer cytolytic activity and promote antigen presentation (10-12).”
BackgroundT-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Kilian, M., Friedrich, M., Sanghvi, K., Green, E., Pusch, S., Kawauchi, D., Löwer, M., Sonner, J. K., Krämer, C., Zaman, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1881 · Cited by 18
Al-Omari, A. A., Cook, K. W., Symonds, P., Skinner, A., Wright, A., Zhu, Y., Coble, V. L., Mohammed, O. J., Choudhury, R. H., Uddin, N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01029-1
Metadata
- Authors
- Ossendorp, F., Mengedé, E., Camps, M., Filius, R., & Melief, C. J. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1998-03-02
- Volume
- 187
- Issue
- 5
- Pages
- 693-702
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2063366670
- Cited by
- 610
- References
- 34
- FWCI
- 14.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.